Enhancing contrast of magnetic resonance imaging in patients with liver cirrhosis

Conveyance times of primovist in hepatobiliary system

Abdallah Ahmed Elbakkoush, Anas Khaleel, Suleman Atique, Albakush Nura Ahmed Mohamed, Isatou Sowe, Chien Tsai Liu

Research output: Contribution to journalArticle

Abstract

Purpose: To determine transit times for excretion of gadoxetic acid (Gd-EOB-DTPA), a recent magnetic resonance imaging (MRI) contrast agent, in hepatobiliary system of patients with liver cirrhosis. Methods: Liver cirrhosis patients that underwent contrast MRI examination at Renai Hospital, Taipei City, Taiwan were included. The patients who have experienced contrast-enhanced abdominal MR examination after injection of 10 mL Gd-EOB-DTPA at 1.5-T MR from December 2009 to March 2011, were included retrospectively. The images were evaluated for the presence of contrast agent in intra-hepatic bile ducts (IHD), common bile duct (CBD), gall bladder and duodenum. Results: The optimal time for arterial phase was from 15 s after injection while the optimal time for portal venous imaging was from 40 s after injection. Furthermore, the optimal time to observe changes was 20 min after contrast initiation of Gd-EOB-DTPA in 39 patients (83 %) in IHD and 37 patients (78.5 %) in CBD. Gall bladder reflux was visible in 26 patients (43 %), and duodenal excretion in 17 patients (36 %). After 30 min of contrast injection, Gd-EOB-DTPA could still be detected in 6 patients (13 %) in IHD and 7 patients (15 %) in CBD, while gall bladder reflux was visible in 10 patients (21 %), and duodenal excretion in 20 patients (55 %). Conclusion: The excretion of Gd-EOB-DTPA can be observed in liver cirrhosis patients.

Original languageEnglish
Pages (from-to)919-924
Number of pages6
JournalTropical Journal of Pharmaceutical Research
Volume16
Issue number4
DOIs
Publication statusPublished - Apr 1 2017

Fingerprint

Liver Cirrhosis
Magnetic Resonance Imaging
Common Hepatic Duct
Common Bile Duct
Bile Ducts
Urinary Bladder
Injections
Contrast Media
gadolinium ethoxybenzyl DTPA
Urban Hospitals
Taiwan
Duodenum

Keywords

  • Common hepatic duct
  • Gadoxetic acid
  • Hepatocellular carcinoma
  • Magnetic resonance imaging (MRI)

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Pharmacology (medical)

Cite this

Enhancing contrast of magnetic resonance imaging in patients with liver cirrhosis : Conveyance times of primovist in hepatobiliary system. / Elbakkoush, Abdallah Ahmed; Khaleel, Anas; Atique, Suleman; Mohamed, Albakush Nura Ahmed; Sowe, Isatou; Liu, Chien Tsai.

In: Tropical Journal of Pharmaceutical Research, Vol. 16, No. 4, 01.04.2017, p. 919-924.

Research output: Contribution to journalArticle

Elbakkoush, Abdallah Ahmed ; Khaleel, Anas ; Atique, Suleman ; Mohamed, Albakush Nura Ahmed ; Sowe, Isatou ; Liu, Chien Tsai. / Enhancing contrast of magnetic resonance imaging in patients with liver cirrhosis : Conveyance times of primovist in hepatobiliary system. In: Tropical Journal of Pharmaceutical Research. 2017 ; Vol. 16, No. 4. pp. 919-924.
@article{c96c27e7e2b847b6a99a6630f25f0edf,
title = "Enhancing contrast of magnetic resonance imaging in patients with liver cirrhosis: Conveyance times of primovist in hepatobiliary system",
abstract = "Purpose: To determine transit times for excretion of gadoxetic acid (Gd-EOB-DTPA), a recent magnetic resonance imaging (MRI) contrast agent, in hepatobiliary system of patients with liver cirrhosis. Methods: Liver cirrhosis patients that underwent contrast MRI examination at Renai Hospital, Taipei City, Taiwan were included. The patients who have experienced contrast-enhanced abdominal MR examination after injection of 10 mL Gd-EOB-DTPA at 1.5-T MR from December 2009 to March 2011, were included retrospectively. The images were evaluated for the presence of contrast agent in intra-hepatic bile ducts (IHD), common bile duct (CBD), gall bladder and duodenum. Results: The optimal time for arterial phase was from 15 s after injection while the optimal time for portal venous imaging was from 40 s after injection. Furthermore, the optimal time to observe changes was 20 min after contrast initiation of Gd-EOB-DTPA in 39 patients (83 {\%}) in IHD and 37 patients (78.5 {\%}) in CBD. Gall bladder reflux was visible in 26 patients (43 {\%}), and duodenal excretion in 17 patients (36 {\%}). After 30 min of contrast injection, Gd-EOB-DTPA could still be detected in 6 patients (13 {\%}) in IHD and 7 patients (15 {\%}) in CBD, while gall bladder reflux was visible in 10 patients (21 {\%}), and duodenal excretion in 20 patients (55 {\%}). Conclusion: The excretion of Gd-EOB-DTPA can be observed in liver cirrhosis patients.",
keywords = "Common hepatic duct, Gadoxetic acid, Hepatocellular carcinoma, Magnetic resonance imaging (MRI)",
author = "Elbakkoush, {Abdallah Ahmed} and Anas Khaleel and Suleman Atique and Mohamed, {Albakush Nura Ahmed} and Isatou Sowe and Liu, {Chien Tsai}",
year = "2017",
month = "4",
day = "1",
doi = "10.4314/tjpr.v16i4.25",
language = "English",
volume = "16",
pages = "919--924",
journal = "Tropical Journal of Pharmaceutical Research",
issn = "1596-5996",
publisher = "Pharmacotherapy Group",
number = "4",

}

TY - JOUR

T1 - Enhancing contrast of magnetic resonance imaging in patients with liver cirrhosis

T2 - Conveyance times of primovist in hepatobiliary system

AU - Elbakkoush, Abdallah Ahmed

AU - Khaleel, Anas

AU - Atique, Suleman

AU - Mohamed, Albakush Nura Ahmed

AU - Sowe, Isatou

AU - Liu, Chien Tsai

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Purpose: To determine transit times for excretion of gadoxetic acid (Gd-EOB-DTPA), a recent magnetic resonance imaging (MRI) contrast agent, in hepatobiliary system of patients with liver cirrhosis. Methods: Liver cirrhosis patients that underwent contrast MRI examination at Renai Hospital, Taipei City, Taiwan were included. The patients who have experienced contrast-enhanced abdominal MR examination after injection of 10 mL Gd-EOB-DTPA at 1.5-T MR from December 2009 to March 2011, were included retrospectively. The images were evaluated for the presence of contrast agent in intra-hepatic bile ducts (IHD), common bile duct (CBD), gall bladder and duodenum. Results: The optimal time for arterial phase was from 15 s after injection while the optimal time for portal venous imaging was from 40 s after injection. Furthermore, the optimal time to observe changes was 20 min after contrast initiation of Gd-EOB-DTPA in 39 patients (83 %) in IHD and 37 patients (78.5 %) in CBD. Gall bladder reflux was visible in 26 patients (43 %), and duodenal excretion in 17 patients (36 %). After 30 min of contrast injection, Gd-EOB-DTPA could still be detected in 6 patients (13 %) in IHD and 7 patients (15 %) in CBD, while gall bladder reflux was visible in 10 patients (21 %), and duodenal excretion in 20 patients (55 %). Conclusion: The excretion of Gd-EOB-DTPA can be observed in liver cirrhosis patients.

AB - Purpose: To determine transit times for excretion of gadoxetic acid (Gd-EOB-DTPA), a recent magnetic resonance imaging (MRI) contrast agent, in hepatobiliary system of patients with liver cirrhosis. Methods: Liver cirrhosis patients that underwent contrast MRI examination at Renai Hospital, Taipei City, Taiwan were included. The patients who have experienced contrast-enhanced abdominal MR examination after injection of 10 mL Gd-EOB-DTPA at 1.5-T MR from December 2009 to March 2011, were included retrospectively. The images were evaluated for the presence of contrast agent in intra-hepatic bile ducts (IHD), common bile duct (CBD), gall bladder and duodenum. Results: The optimal time for arterial phase was from 15 s after injection while the optimal time for portal venous imaging was from 40 s after injection. Furthermore, the optimal time to observe changes was 20 min after contrast initiation of Gd-EOB-DTPA in 39 patients (83 %) in IHD and 37 patients (78.5 %) in CBD. Gall bladder reflux was visible in 26 patients (43 %), and duodenal excretion in 17 patients (36 %). After 30 min of contrast injection, Gd-EOB-DTPA could still be detected in 6 patients (13 %) in IHD and 7 patients (15 %) in CBD, while gall bladder reflux was visible in 10 patients (21 %), and duodenal excretion in 20 patients (55 %). Conclusion: The excretion of Gd-EOB-DTPA can be observed in liver cirrhosis patients.

KW - Common hepatic duct

KW - Gadoxetic acid

KW - Hepatocellular carcinoma

KW - Magnetic resonance imaging (MRI)

UR - http://www.scopus.com/inward/record.url?scp=85018413664&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018413664&partnerID=8YFLogxK

U2 - 10.4314/tjpr.v16i4.25

DO - 10.4314/tjpr.v16i4.25

M3 - Article

VL - 16

SP - 919

EP - 924

JO - Tropical Journal of Pharmaceutical Research

JF - Tropical Journal of Pharmaceutical Research

SN - 1596-5996

IS - 4

ER -